‘절망의 암’으로 불리는 전이성 췌장암, 생존 시간 두 배 늘어났다 [건강한겨레]

A new treatment approach has significantly improved survival rates for patients with metastatic pancreatic cancer, a disease often referred to as the "cancer of despair." This innovative therapy has effectively doubled the average survival time for individuals diagnosed with this aggressive form of cancer. The breakthrough offers a beacon of hope for patients and their families facing a condition with historically poor prognoses. Further details on the specific treatment and its mechanisms are expected to be released.

This development offers a crucial advancement in treating a notoriously difficult cancer, potentially extending lives and improving outcomes for many patients.